Evidence map›Paper›PMID 32199709›Full record

ReviewAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2020

Diagnosis and Management of Pulmonary Hypertension in Patients With CKD.

Carl P Walther, Vijay Nambi, Nicola A Hanania, Sankar D Navaneethan

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04842591 (Characteristics of Pulmonary Vascular Changes in Patients With Kidney Transplantation), which is not on this map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04842591 active not recruitingnot on this map

Characteristics of Pulmonary Vascular Changes in Patients With Kidney Transplantation

TypeobservationalSponsorMedical University of GrazRan2020 to 2027Enrolled60ConditionsPulmonary Hypertension, Kidney Transplantation, HaemodialysisArmsexercise echocardiography
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Incident Pulmonary Hypertension and Its Risk Factors in CKD.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Carl P WaltherSelzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX. Electronic address: carl.walther@bcm.edu.
Vijay NambiMicheal E DeBakey Veterans Affairs Medical Center, Department of Medicine, Baylor College of Medicine, Houston, TX; Sections of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX.
Nicola A HananiaPulmonary, Critical Care and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX.
Sankar D NavaneethanSelzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX; Section of Nephrology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX. Electronic address: sankar.navaneethan@bcm.edu.
Baylor College of Medicine · US

Funding

Visceral Adiposity and Physical Fitness in CKDR01DK101500 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI NAVANEETHAN, SANKAR DASS · 2014 to 2018
$3.0M
Biomarker guided therapies in Stage A/B Heart FailureI01CX001112 · VA · MICHAEL E DEBAKEY VA MEDICAL CENTER · PI NAMBI, VIJAY · 2015 to 2019
–
CSRD VA I01 CX001112NIDDK NIH HHS R01 DK101500
6 · The paper itself

Abstract

Pulmonary hypertension (PH) is a highly prevalent and important condition in adults with chronic kidney disease (CKD). In this review, we summarize the definition of PH, discuss its pathophysiology and classifications, and describe diagnostic and management strategies in patients with CKD, including those with kidney failure treated by kidney replacement therapy. In the general population, PH is classified into 5 groups based on clinical presentation, pathology, hemodynamics, and management strategies. In this classification system, PH in CKD is placed in a diverse group with unclear or multifactorial mechanisms, although underlying cardiovascular disease may account for most cases. CKD may itself directly incite pulmonary circulatory dysfunction and remodeling through uremic toxins, inflammation, endothelial dysfunction, and altered vasoregulation. Despite several studies describing the higher prevalence of PH in CKD and kidney failure, along with an association with poor outcomes, high-quality evidence is not available for its diagnostic and management strategies in those with CKD. In CKD not requiring kidney replacement therapy, volume management along with treatment of underlying risk factors for PH are critical. In those receiving hemodialysis, options are limited and transition to peritoneal dialysis may be considered if recurrent hypotension precludes optimal volume control.

Indexed as

Blood VolumeHypertension, PulmonaryRenal Insufficiency, ChronicAdultHumansPatient Care ManagementPrevalenceRenal Replacement TherapyRisk FactorsChronic kidney disease (CKD)deathdialysisend-stage renal disease (ESRD)heart failurekidney failuremean pulmonary arterial pressure (PAPm)pulmonary arterial hypertension (PAH)pulmonary circulatory dysfunctionpulmonary hypertension (PH)reviewvascular remodelingvolume management

Identifiers

PMID32199709
PMCPMC7247937
OpenAlexW3011235844

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.